مورد إلكتروني
Lack of efficacy of mTOR inhibitors and ACE pathway inhibitors as antifibrotic agents in evolving and established fibrosis in Mdr2-/- mice
| العنوان: | Lack of efficacy of mTOR inhibitors and ACE pathway inhibitors as antifibrotic agents in evolving and established fibrosis in Mdr2-/- mice |
|---|---|
| المصدر: | Liver International |
| بيانات النشر: | Wiley-Blackwell Publishing Ltd 2015 |
| تفاصيل مُضافة: | Bridle, Kim Sobbe, Amy de Guzman, Erika Santrampurwala, Nishreen Jaskowski, Lesley-Anne Clouston, Andrew Campbell, Catherine Subramaniam, V. Nathan |
| نوع الوثيقة: | Electronic Resource |
| مستخلص: | Background & Aims - Mammalian target of rapamycin and angiotensin-converting enzyme inhibition has been shown to have antifibrotic activity in models of liver fibrosis. The aim of our study was to determine the efficacy of rapamycin, everolimus, irbesartan and captopril, alone and in combination, as antifibrotic agents in the Mdr2-/- model of cholestasis both in early injury and established disease. Methods - Mdr2-/- mice were treated for 4 weeks with vehicle, rapamycin (1 mg/kg) or everolimus (5 mg/kg) every second day or with captopril (30 mg/kg/day), irbesartan (10 mg/kg/day) or vehicle. Further groups of 3-week-old Mdr2-/- mice were treated with rapamycin and irbesartan in combination (1 mg/kg/day and 10 mg/kg/day) or with rapamycin (2 mg/kg/day) for 4 weeks. Liver injury and fibrosis were compared between treated and untreated animals. Results - There were no significant improvements in liver injury, histology, hepatic hydroxyproline or profibrogenic gene expression following treatment with rapamycin, everolimus, captopril or irbesartan at any time point studied. Likewise, there were no improvements in liver histology or profibrogenic gene expression following combination therapy or high-dose rapamycin treatment. Conclusions - The antifibrotic effects of rapamycin, everolimus, captopril and irbesartan seen in other models of fibrosis were not replicated in the Mdr2-/- model in this study. This highlights the clear need to test specific antifibrotic agents in a number of different animal models. We believe this animal model is ideal to study usefulness of antifibrotic agents in cholestatic liver disease because of the similarity in genetics and hepatic histopathology to human cholestatic liver disease. |
| مصطلحات الفهرس: | ACE inhibitors, Angiotensin II Type 1 Receptor Blockers, Angiotensin-Converting Enzyme Inhibitors, Animals, Biphenyl Compounds, Combination, Drug Therapy, Experimental, Knockout, Liver Cirrhosis, Mdr2, Mice, P-Glycoproteins, P-glycoprotein 2, Protein Kinase Inhibitors, Renin-Angiotensin System, Sirolimus, Species Specificity, TOR Serine-Threonine Kinases, Tetrazoles, Time Factors, angiotensin 1 receptor antagonist, animal, antagonists and inhibitors, biphenyl derivative, captopril, comparative study, deficiency, dipeptidyl carboxypeptidase inhibitor, drug combination, drug effects, enzymology, everolimus, female, fibrosis, gene expression regulation, genetics, hydroxyproline, irbesartan, knockout mouse, liver, mTOR inhibitors, mTOR protein, male, metabolism, mouse, multidrug resistance protein, pathology, protein kinase inhibitor, rapamycin, renin angiotensin aldosterone system, signal transduction, species difference, target of rapamycin kinase, tetrazole derivative, time, Contribution to Journal |
| URL: | doi:10.1111/liv.12494 Bridle, Kim, Sobbe, Amy, de Guzman, Erika, Santrampurwala, Nishreen, Jaskowski, Lesley-Anne, Clouston, Andrew, Campbell, Catherine, & Subramaniam, V. Nathan (2015) Lack of efficacy of mTOR inhibitors and ACE pathway inhibitors as antifibrotic agents in evolving and established fibrosis in Mdr2-/- mice. Liver International, 35(4), pp. 1451-1463. |
| الإتاحة: | Open access content. Open access content Consult author(s) regarding copyright matters This work is covered by copyright. Unless the document is being made available under a Creative Commons Licence, you must assume that re-use is limited to personal use and that permission from the copyright owner must be obtained for all other uses. If the document is available under a Creative Commons License (or other specified license) then refer to the Licence for details of permitted re-use. It is a condition of access that users recognise and abide by the legal requirements associated with these rights. If you believe that this work infringes copyright please provide details by email to qut.copyright@qut.edu.au |
| أرقام أخرى: | ATUTQ oai:eprints.qut.edu.au:101154 Faculty of Health; Institute of Health and Biomedical Innovation; School of Biomedical Sciences 974838539 |
| المصدر المساهم: | QUEENSLAND UNIV OF TECH From OAIster®, provided by the OCLC Cooperative. |
| رقم الانضمام: | edsoai.ocn974838539 |
| قاعدة البيانات: | OAIster |
| الوصف غير متاح. |